Sale

Cancer Therapeutics Market

Global Cancer Therapeutics Market Size, Share, Analysis, Forecast: By Therapy Type: Chemotherapy, Immunotherapy, Targeted Therapy, Hormonal Therapy, Radiation Therapy, Stem Cell Transplant, Others; By Drug Class; By Route of Administration; By Cancer Type; By Distribution Channel; Regional Analysis; Supplier Landscape; 2024-2032

Global Cancer Therapeutics Market Outlook

The global cancer therapeutics market size attained a value of USD 149.92 billion in 2023, driven by increase in research and development activities, rising cooperation among pharmaceutical companies, rising geriatric population, rising demand for personalised medicine, and increased investment in the healthcare sector. The market is anticipated to grow at a CAGR of 10.4% during the forecast period of 2024-2032 to attain a value of USD 365.25 billion by 2032.

 

The cancer therapeutics market is being driven by the increased investment by companies in the R&D sector. The increasing incidences of cancer across the globe are also adding to the cancer therapeutics market growth.

 

Global Cancer Therapeutics Market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Market Segmentation

Cancer therapy includes the use and administration of chemotherapy and oncology drugs for the treatment of cancer. It is a type of treatment that identifies and attacks particular kinds of cancer cells with less damage to ordinary cells with the help of drugs or other substances. Some targeted therapies block certain enzymes, proteins, or other molecules that are engaged in cancer cell development.

 

Global Cancer Therapeutics Market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

The cancer therapeutics market can be divided on the basis of segments like application and top-selling drugs.

The industry can be broadly categorised based on its application into:

  • Blood cancer
  • Lung cancer
  • Breast cancer
  • Colorectal cancer
  • Prostate cancer
  • Cervical cancer
  • Head and neck cancer
  • Glioblastoma
  • Malignant Meningioma
  • Mesothelioma
  • Melanoma
  • Others

The cancer therapeutics market can be divided on the basis of its top-selling drugs as Revlimid, Avastin, Herceptin, Rituxan, Opdivo, Gleevec, Velcade, Imbruvica, Ibrance, Zytiga, Alimta, Xtandi, Tarceva, Perjeta, and Temodar, among others.

The EMR report looks into the regional cancer therapeutics markets like North America, Latin America, Europe, the Middle East and Africa, and the Asia Pacific.

 

Market Analysis

An increase in the incidences of cancer, rising cooperation among pharmaceutical companies, and growing innovation in the cancer-research sector are factors that are driving the growth of the cancer therapeutics industry. It is anticipated that the geriatric population will increase over the forecast period, further increasing the demand for cancer therapy. Further, the rising demand for personalised medicine and increased investment in the healthcare sector, particularly in developing countries, is providing the cancer therapeutics market with new growth opportunities. Some of the factors that restrict cancer therapeutics market growth are high costs connected with oncology drug development and adverse effects associated with cancer therapy.

 

Global Cancer Therapeutics Market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Competitive Landscape

The report presents a detailed analysis of the following key players in the global cancer therapeutics market, looking into their capacity, competitive landscape, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:

  • AbbVie Inc. (NYSE: ABBV)
  • Astellas Pharma Inc. 
  • Bristol Myers Squibb Company 
  • Celgene Corporation
  • F. Hoffmann-La Roche Ltd. 
  • Johnson & Johnson 
  • Merck & Co., Inc. 
  • Novartis AG 
  • Pfizer Inc. 
  • Others

The EMR report gives an in-depth insight into the industry by providing a SWOT analysis as well as an analysis of Porter’s five forces.

 

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Therapy Type
  • Drug Class
  • Route of Administration
  • Cancer Type
  • Distribution Channel
  • Region
Breakup by Therapy Type
  • Chemotherapy
  • Immunotherapy
  • Targeted Therapy
  • Hormonal Therapy
  • Radiation Therapy
  • Stem Cell Transplant
  • Gene Therapy
  • Other Emerging Therapies
Breakup by Drug Class
  • Alkylating Agents
  • Antimetabolites
  • Antitumor Antibiotics
  • Topoisomerase Inhibitors
  • Mitotic Inhibitors
  • Hormone Therapies
  • Immune Checkpoint Inhibitors
  • Others
Breakup by Route of Administration
  • Oral
  • Intravenous
  • Subcutaneous
  • Intramuscular
  • Topical
  • Others
Breakup by Cancer Type
  • Lung Cancer
  • Breast Cancer
  • Prostate Cancer
  • Colorectal Cancer
  • Skin Cancer
  • Blood Cancer (Leukemia, Lymphoma, etc.)
  • Gastrointestinal Cancer
  • Gynecological Cancer
  • Others
Breakup by Distribution Channel
  • Hospital pharmacies
  • Retail pharmacies
  • Online pharmacies
  • Specialty pharmacies
Breakup by Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
Market Dynamics
  • Market Drivers and Constraints
  • SWOT Analysis
  • Porter’s Five Forces Model 
  • Key Demand Indicators
  • Key Price Indicators
  • Industry Events, Initiatives, and Trends 
  • Value Chain Analysis
Supplier Landscape
  • Market Structure
  • Company Profiles
    • Financial Analysis
    • Product Portfolio
    • Demographic Reach and Achievements
    • Mergers and Acquisitions
    • Certifications
Companies Covered
  • AstraZeneca
  • Bristol-Myers Squibb
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis International AG
  • Pfizer Inc.
  • Sanofi
  • Takeda Pharmaceutical Company Limited
  • Celgene Corporation
  • Amgen Inc.
  • Gilead Sciences, Inc.
  • Bayer AG
  • AbbVie Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Genentech
  • Seattle Genetics, Inc.
  • Aimmune Therapeutics

 

*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.

1    Preface
    1.1    Objectives of the Study
    1.2    Key Assumptions 
    1.3    Report Coverage – Key Segmentation and Scope  
    1.4    Research Methodology
2    Executive Summary
3    Cancer Overview

    3.1    Guidelines and Stages
    3.2    Pathophysiology
    3.3    Screening and Diagnosis
    3.4    Treatment Pathway 
4    Patient Profile
    4.1    Patient Profile Overview
    4.2    Patient Psychology and Emotional Impact Factors
    4.3    Risk Assessment and Treatment Success Rate
5    Cancer Epidemiology Analysis
    5.1    Epidemiology Overview (2016-2031)
    5.2    North America Cancer Epidemiology (2016-2031)
    5.3    Europe Cancer Epidemiology (2016-2031)
    5.4    Asia-Pacific Cancer Epidemiology (2016-2031)
    5.5    Latin America Cancer Epidemiology (2016-2031)
    5.6    Middle East & Africa Cancer Epidemiology (2016-2031)
6    Global Cancer Therapeutics Market Overview 
    6.1    Global Cancer Therapeutics Market Historical Value (2017-2023) 
    6.2    Global Cancer Therapeutics Market Forecast Value (2024-2032)
7    Global Cancer Therapeutics Market Landscape
    7.1    Global Cancer Therapeutics Company Landscape
        7.1.1    Analysis by Year of Establishment
        7.1.2    Analysis by Company Size
        7.1.3    Analysis by Region
    7.2    Global Cancer Therapeutics Product Landscape
        7.2.1    Analysis by Therapy Type
        7.2.2    Analysis by Drug Class
        7.2.3    Analysis by Route of Administration
        7.2.4    Analysis by Cancer Type
        7.2.5    Analysis by Distribution Channel
8    Cancer Therapeutics Challenges and Unmet Needs
    8.1    Treatment Pathway Challenges
    8.2    Compliance and Drop-Out Analysis
    8.3    Awareness and Prevention Gaps
9    Cost of Treatment
10    Global Cancer Therapeutics Market Dynamics

    10.1    Market Drivers and Constraints
    10.2    SWOT Analysis
    10.3    Porter’s Five Forces Model 
    10.4    Key Demand Indicators
    10.5    Key Price Indicators
    10.6    Industry Events, Initiatives, and Trends 
    10.7    Value Chain Analysis
11    Global Cancer Therapeutics Market Segmentation
    11.1    Global Cancer Therapeutics Market by Therapy Type
        11.1.1    Market Overview
        11.1.2    Chemotherapy
        11.1.3    Immunotherapy
            11.1.3.1    Checkpoint Inhibitors
            11.1.3.2    Car-T Cell Therapy
            11.1.3.3    Cancer Vaccines
            11.1.3.4    Cytokine Therapy
        11.1.4    Targeted Therapy
            11.1.4.1    Tyrosine Kinase Inhibitors
            11.1.4.2    Monoclonal Antibodies
            11.1.4.3    Proteasome Inhibitors
        11.1.5    Hormonal Therapy
        11.1.6    Radiation Therapy
        11.1.7    Stem Cell Transplant
        11.1.8    Gene Therapy
        11.1.9    Other Emerging Therapies
    11.2    Global Cancer Therapeutics Market by Drug Class
        11.2.1    Market Overview
        11.2.2    Alkylating Agents
        11.2.3    Antimetabolites
        11.2.4    Antitumor Antibiotics
        11.2.5    Topoisomerase Inhibitors
        11.2.6    Mitotic Inhibitors
        11.2.7    Hormone Therapies
        11.2.8    Immune Checkpoint Inhibitors
        11.2.9    Others
    11.3    Global Cancer Therapeutics Market by Route of Administration
        11.3.1    Market Overview
        11.3.2    Oral
        11.3.3    Intravenous
        11.3.4    Subcutaneous
        11.3.5    Intramuscular
        11.3.6    Topical
        11.3.7    Others
    11.4    Global Cancer Therapeutics Market by Cancer Type
        11.4.1    Market Overview
        11.4.2    Lung Cancer
        11.4.3    Breast Cancer
        11.4.4    Prostate Cancer
        11.4.5    Colorectal Cancer
        11.4.6    Skin Cancer
        11.4.7    Blood Cancer (Leukemia, Lymphoma, etc.)
        11.4.8    Gastrointestinal Cancer
        11.4.9    Gynecological Cancer
        11.4.10    Others
    11.5    Global Cancer Therapeutics Market by Distribution Channel
        11.5.1    Market Overview
        11.5.2    Hospital pharmacies
        11.5.3    Retail pharmacies
        11.5.4    Online pharmacies
        11.5.5    Specialty pharmacies
    11.6    Global Cancer Therapeutics Market by Region
        11.6.1    Market Overview
        11.6.2    North America 
        11.6.3    Europe
        11.6.4    Asia Pacific
        11.6.5    Latin America
        11.6.6    Middle East and Africa
12    North America Cancer Therapeutics Market
    12.1    Market Share by Country
    12.2    United States of America
    12.3    Canada
13    Europe Cancer Therapeutics Market
    13.1    Market Share by Country
    13.2    United Kingdom
    13.3    Germany
    13.4    France
    13.5    Italy
    13.6    Others
14    Asia Pacific Cancer Therapeutics Market
    14.1    Market Share by Country
    14.2    China
    14.3    Japan
    14.4    India
    14.5    ASEAN
    14.6    Australia
    14.7    Others
15    Latin America Cancer Therapeutics Market
    15.1    Market Share by Country
    15.2    Brazil
    15.3    Argentina
    15.4    Mexico
    15.5    Others
16    Middle East and Africa Cancer Therapeutics Market
    16.1    Market Share by Country
    16.2    Saudi Arabia
    16.3    United Arab Emirates
    16.4    Nigeria
    16.5    South Africa
    16.6    Others
17    Patent Analysis
    17.1    Analysis by Type of Patent
    17.2    Analysis by Publication year
    17.3    Analysis by Issuing Authority
    17.4    Analysis by Patent Age
    17.5    Analysis by CPC Analysis
    17.6    Analysis by Patent Valuation 
    17.7    Analysis by Key Players
18    Grants Analysis
    18.1    Analysis by year
    18.2    Analysis by Amount Awarded
    18.3    Analysis by Issuing Authority
    18.4    Analysis by Grant Application
    18.5    Analysis by Funding Institute
    18.6    Analysis by NIH Departments
    18.7    Analysis by Recipient Organization 
19    Clinical Trials Analysis 
    19.1     Analysis by Trial Registration Year 
    19.2    Analysis by Trial Status 
    19.3    Analysis by Trial Phase 
    19.4    Analysis by Therapeutic Area 
    19.5    Analysis by Geography 
20    Funding Analysis
    20.1    Analysis by Funding Instances
    20.2    Analysis by Type of Funding
    20.3    Analysis by Funding Amount
    20.4    Analysis by Leading Players
    20.5    Analysis by Leading Investors
    20.6    Analysis by Geography
21    Partnership and Collaborations Analysis
    21.1    Analysis by Partnership Instances
    21.2    Analysis by Type of Partnership
    21.3    Analysis by Leading Players
    21.4    Analysis by Geography
22    Regulatory Framework
    22.1    Regulatory Overview
        22.1.1    US FDA
        22.1.2    EU EMA
        22.1.3    INDIA CDSCO
        22.1.4    JAPAN PMDA
        22.1.5    Others
23    Supplier Landscape
    23.1    AstraZeneca
        23.1.1    Financial Analysis
        23.1.2    Product Portfolio
        23.1.3    Demographic Reach and Achievements
        23.1.4    Mergers and Acquisitions
        23.1.5    Certifications
    23.2    Bristol-Myers Squibb
        23.2.1    Financial Analysis
        23.2.2    Product Portfolio
        23.2.3    Demographic Reach and Achievements
        23.2.4    Mergers and Acquisitions
        23.2.5    Certifications
    23.3    Eli Lilly and Company
        23.3.1    Financial Analysis
        23.3.2    Product Portfolio
        23.3.3    Demographic Reach and Achievements
        23.3.4    Mergers and Acquisitions
        23.3.5    Certifications
    23.4    F. Hoffmann-La Roche AG
        23.4.1    Financial Analysis
        23.4.2    Product Portfolio
        23.4.3    Demographic Reach and Achievements
        23.4.4    Mergers and Acquisitions
        23.4.5    Certifications
    23.5    GlaxoSmithKline
        23.5.1    Financial Analysis
        23.5.2    Product Portfolio
        23.5.3    Demographic Reach and Achievements
        23.5.4    Mergers and Acquisitions
        23.5.5    Certifications
    23.6    Johnson & Johnson
        23.6.1    Financial Analysis
        23.6.2    Product Portfolio
        23.6.3    Demographic Reach and Achievements
        23.6.4    Mergers and Acquisitions
        23.6.5    Certifications
    23.7    Merck & Co., Inc.
        23.7.1    Financial Analysis
        23.7.2    Product Portfolio
        23.7.3    Demographic Reach and Achievements
        23.7.4    Mergers and Acquisitions
        23.7.5    Certifications
    23.8    Novartis International AG
        23.8.1    Financial Analysis
        23.8.2    Product Portfolio
        23.8.3    Demographic Reach and Achievements
        23.8.4    Mergers and Acquisitions
        23.8.5    Certifications
    23.9    Pfizer Inc.
        23.9.1    Financial Analysis
        23.9.2    Product Portfolio
        23.9.3    Demographic Reach and Achievements
        23.9.4    Mergers and Acquisitions
        23.9.5    Certifications
    23.10    Sanofi
        23.10.1    Financial Analysis
        23.10.2    Product Portfolio
        23.10.3    Demographic Reach and Achievements
        23.10.4    Mergers and Acquisitions
        23.10.5    Certifications
    23.11    Takeda Pharmaceutical Company Limited
        23.11.1    Financial Analysis
        23.11.2    Product Portfolio
        23.11.3    Demographic Reach and Achievements
        23.11.4    Mergers and Acquisitions
        23.11.5    Certifications
    23.12    Celgene Corporation
        23.12.1    Financial Analysis
        23.12.2    Product Portfolio
        23.12.3    Demographic Reach and Achievements
        23.12.4    Mergers and Acquisitions
        23.12.5    Certifications
    23.13    Amgen Inc.
        23.13.1    Financial Analysis
        23.13.2    Product Portfolio
        23.13.3    Demographic Reach and Achievements
        23.13.4    Mergers and Acquisitions
        23.13.5    Certifications
    23.14    Gilead Sciences, Inc.
        23.14.1    Financial Analysis
        23.14.2    Product Portfolio
        23.14.3    Demographic Reach and Achievements
        23.14.4    Mergers and Acquisitions
        23.14.5    Certifications
    23.15    Bayer AG
        23.15.1    Financial Analysis
        23.15.2    Product Portfolio
        23.15.3    Demographic Reach and Achievements
        23.15.4    Mergers and Acquisitions
        23.15.5    Certifications
    23.16    AbbVie Inc.
        23.16.1    Financial Analysis
        23.16.2    Product Portfolio
        23.16.3    Demographic Reach and Achievements
        23.16.4    Mergers and Acquisitions
        23.16.5    Certifications
    23.17    Regeneron Pharmaceuticals, Inc.
        23.17.1    Financial Analysis
        23.17.2    Product Portfolio
        23.17.3    Demographic Reach and Achievements
        23.17.4    Mergers and Acquisitions
        23.17.5    Certifications
    23.18    Genentech
        23.18.1    Financial Analysis
        23.18.2    Product Portfolio
        23.18.3    Demographic Reach and Achievements
        23.18.4    Mergers and Acquisitions
        23.18.5    Certifications
    23.19    Seattle Genetics, Inc.
        23.19.1    Financial Analysis
        23.19.2    Product Portfolio
        23.19.3    Demographic Reach and Achievements
        23.19.4    Mergers and Acquisitions
        23.19.5    Certifications
    23.20    Aimmune Therapeutics
        23.20.1    Financial Analysis
        23.20.2    Product Portfolio
        23.20.3    Demographic Reach and Achievements
        23.20.4    Mergers and Acquisitions
        23.20.5    Certifications
24    Global Cancer Therapeutics Market - Distribution Model (Additional Insight)
    24.1    Overview 
    24.2    Potential Distributors 
    24.3    Key Parameters for Distribution Partner Assessment 
25    Key Opinion Leaders (KOL) Insights (Additional Insight)
26    Company Competitiveness Analysis (Additional Insight)

    26.1    Very Small Companies
    26.2    Small Companies
    26.3    Mid-Sized Companies
    26.4    Large Companies
    26.5    Very Large Companies
27    Payment Methods (Additional Insight)
    27.1    Government Funded
    27.2    Private Insurance
    27.3    Out-of-Pocket

 

*Additional insights provided are customisable as per client requirements.

Key Questions Answered in the Report

In 2023, the global market for cancer therapeutics reached a value of USD 149.92 billion.

The market is anticipated to grow at a CAGR of 10.4% during the forecast period of 2024-2032 to reach a value of USD 365.25 billion by 2032.

The major drivers of the market include the increase in research and development activities, rising cooperation among pharmaceutical companies, rising geriatric population, rising demand for personalised medicine, and increased investment in the healthcare sector.

Increasing incidences of cancer, and growing innovation in the cancer-research sector are the key industry trends propelling the market's growth.

The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.

The cancer therapeutics market can be divided on the basis of its top-selling drugs into Revlimid, Avastin, Herceptin, Rituxan, Opdivo, Gleevec, Velcade, Imbruvica, Ibrance, Zytiga, Alimta, Xtandi, Tarceva, Perjeta, and Temodar, among others.

Cancer therapeutics find their major application in sectors like blood cancer, lung cancer, breast cancer, colorectal cancer, prostate cancer, cervical cancer, head and neck cancer, glioblastoma, malignant meningioma, mesothelioma, and melanoma, among others.

The major players in the industry are AbbVie Inc. , Astellas Pharma Inc., Bristol-Myers Squibb Company, Celgene Corporation, F. Hoffmann-La Roche Ltd., Johnson & Johnson, Merck & Co., Inc., Novartis AG, and Pfizer Inc., among others.

Purchase Full Report

Mini Report

$ 3499     $2999
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$ 5999     $5499
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update
most popular

Five User License

$ 8299     $7499
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$ 10499     $9499
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

NEWSLETTER